Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Multiple Myeloma"
topic_facet:"Phase: Phase 2"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Multiple+Myeloma%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+2%22&lookfor=%22Myeloma%22&type=Subject
PubPharm (955)
1
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients : A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS : Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) : Molecular Analysis for Therapy Choice (MATCH)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation : A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients : Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma : A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma : Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) : MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) : MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Except Basal Cell Skin Carcinoma) With Smoothened (SMO) or Patched 1 (PTCH1) Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) : MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[96]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Multiple Myeloma
Filter aufheben
Thema: Phase: Phase 2
Medienart
955
Aufsätze
955
E-Artikel
955
E-Ressourcen
Zeitschriftentitel
955
ClinicalTrials.gov
Thema
955
610
Multiple Myeloma
Phase: Phase 2
955
Study Type: Interventional
814
Neoplasms, Plasma Cell
382
Recruitment Status: Completed
279
Medical Condition: Multiple Myeloma
165
Recruitment Status: Active, not recruiting
154
Recruitment Status: Recruiting
133
Lymphoma
133
Recruitment Status: Terminated
82
Leukemia
66
Myelodysplastic Syndromes
57
Neoplasms
54
Recruitment Status: Withdrawn
50
Leukemia, Lymphocytic, Chronic, B-Cell
49
Smoldering Multiple Myeloma
48
Lymphoma, Non-Hodgkin
48
Plasmacytoma
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
556
2020-
377
2010-2019
22
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
955
Englisch
Haven't found what you're looking for?
Wird geladen...